Dublin-based Actavis to buy Forest Labs for $25 billion #recent #pharmaceutical #news

Posted On Jan 7 2018 by

#forest pharma # Dublin-based Actavis to buy Forest Labs for $25 billion Actavis. the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 per cent to Forest’s Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Forest had a market value of $19.3 billion at the close of trading last Friday. Dublin-headquartered Actavis was the most active buyer of drug companies over the past three …


Horizon Pharma to buy Lake Forest company for $510 million – Chicago Tribune #global #pharmaceutical #industry

Posted On Jan 7 2018 by

#horizon pharma # Horizon Pharma to buy Lake Forest company for $510 million Fast-growing Horizon Pharma is spending $510 million to buy Crealta Holdings, of Lake Forest, which makes the only approved medicine for chronic refractory gout, a disorder that affects about 50,000 Americans. The definitive agreement, announced Friday, is the latest move by Horizon to become a major pharmaceutical player, primarily through acquisitions. The company said last month its sales will double in the next four years, led by its orphan drug business. Orphan drugs, which treat rare diseases, often command high prices and profits. Horizon Pharma expects sales …


Forest pharma #usv #pharma

Posted On Dec 25 2017 by

#forest pharma # Actavis/Forest Laboratories Before outdoing itself with its $66 billion Allergan ($AGN) buyout, Actavis ($ACT) had the biggest buy of 2014’s first half with its acquisition of Forest Labs. And with two deal-minded CEOs at the helm, this one happened quickly. When the pair first met at 2014’s J.P. Morgan Healthcare Conference, then-Actavis CEO Paul Bisaro had already merged Watson Pharmaceuticals with generics maker Actavis and then nabbed Ireland’s Warner Chilcott to build up on the branded side. Brand-new Forest CEO Brent Saunders had just stepped into the skipper’s chair after Valeant ($VRX) bought up Bausch + Lomb, …


Forest pharma #rexall #pharma #plus

Posted On Nov 30 2017 by

#forest pharma # Actavis/Forest Laboratories Before outdoing itself with its $66 billion Allergan ($AGN) buyout, Actavis ($ACT) had the biggest buy of 2014’s first half with its acquisition of Forest Labs. And with two deal-minded CEOs at the helm, this one happened quickly. When the pair first met at 2014’s J.P. Morgan Healthcare Conference, then-Actavis CEO Paul Bisaro had already merged Watson Pharmaceuticals with generics maker Actavis and then nabbed Ireland’s Warner Chilcott to build up on the branded side. Brand-new Forest CEO Brent Saunders had just stepped into the skipper’s chair after Valeant ($VRX) bought up Bausch + Lomb, …


Actavis to Buy Forest Laboratories for $25 Billion #pharma #mba

Posted On Nov 30 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


Allergan Forest Jobs, Reviews – Working at Allergan Forest – #pharma #bio

Posted On Nov 30 2017 by

#forest pharma # Allergan + Forest Forest Europe has been creating cutting-edge pharmaceutical products and a range of global healthcare brands for several decades. Our innovative prescription medicine business is dedicated to improving the lives of those with challenging conditions like cystic fibrosis and bronchiectasis, while our non-prescription healthcare range includes market-leading brands. Since 1979, when Forest Laboratories first broke ground in Europe with the acquisition of Pharmax Ltd, in the UK, Forest Europe has been a critical driver of the Company s global growth. Today, Forest Europe has divisions in the UK and Ireland, and we are currently building …


Forest Laboratories to Acquire Furiex Pharmaceuticals #sandoz #pharma

Posted On Nov 24 2017 by

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …


Forest Laboratories to Acquire Furiex Pharmaceuticals #leo #pharma

Posted On Oct 4 2017 by

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …


Actavis to Buy Forest Laboratories for $25 Billion #pharma #industries

Posted On Oct 4 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


Forest Laboratories, Inc #pharmaceutical #industry #trends

Posted On Oct 4 2017 by

#forest pharma # Forest Laboratories, Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? …